Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MCAC Advises AMD Manufacturers To Conduct Randomized, Controlled Trials

This article was originally published in The Gray Sheet

  • News

Executive Summary

Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, CMS' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore

You may also be interested in...



TEC Says More Evidence Is Required To Judge AMD Combination Therapies

More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center

TEC Says More Evidence Is Required To Judge AMD Combination Therapies

More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center

MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration

CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to evaluate the evidence for age-related macular degeneration (AMD) treatments

Table

View full table

Tags:
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT022978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By